高危复发/难治性霍奇金淋巴瘤的双次造血干细胞移植:一项LYSA研究
该研究在法国全国数据库前瞻性登记的120例高危复发/难治性霍奇金淋巴瘤患者中,评估双次自体移植或自体移植后异基因移植的耐受性与疗效。中位随访43个月,全人群2年无进展生存率为56%,接受双次移植者为71%。作者认为双次移植有效但移植相关死亡率仍高,其获益需与维布妥昔单抗为基础的移植后巩固策略的疗效相权衡。
要点
- 120例高危复发/难治性霍奇金淋巴瘤患者中,完全缓解率60%,部分缓解率32%,治疗失败8%。
- 115例(96%)接受首次自体移植,73例(61%)接受双次移植,其中异基因移植44例(60%)、自体移植29例(40%)。
- 全人群2年无进展生存率56%(95%CI 46-65%),双次移植者71%(95%CI 49-84%)。
核心结论
- 作者认为双次干细胞移植对高危复发/难治性霍奇金淋巴瘤患者有效,但移植相关死亡率仍高。
- 作者建议双次干细胞移植的获益应与高危复发/难治性霍奇金淋巴瘤患者中以维布妥昔单抗为基础的移植后巩固策略的疗效相权衡。
研究设计与样本
- 研究在法国全国数据库前瞻性登记的120例霍奇金淋巴瘤患者中评估双次自体移植或自体移植后异基因移植的耐受性与疗效。
- 患者中位年龄26岁(范围14-56岁)。
- 中位随访43个月(范围4.8-73.7个月)。
主要发现
- 完全缓解率为60%,其中33%在单线挽救治疗后达到,另27%在两种或以上挽救方案后达到。
- 部分缓解率为32%,8%的患者治疗失败。
- 115例(96%)患者接受首次自体移植,73例(61%)接受双次移植,其中异基因移植44例(60%)、自体移植29例(40%)。
- 全人群2年无进展生存率为56%(95%CI 46-65%),接受双次移植患者的2年无进展生存率为71%(95%CI 49-84%)。
- 双次移植中观察到20例死亡(17%),其中10例为移植相关死亡(异基因移植6例、自体移植4例)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tandem stem cell transplantation (SCT) is an option for high-risk relapsed/refractory Hodgkin Lymphoma (HL) patients. We evaluated the tolerance/efficacy of double autologous or autologous SCT (ASCT) followed by allogenic SCT (alloSCT) in 120 HL patients prospectively registered on a French nationwide database. Median age was 26 (14-56) years. Complete remission rate was 60%, including 33% after a single line, and another 27% after two or more salvage regimens. Partial response rate was 32%, and 8% suffered treatment failure. Overall, 115 (96%) patients underwent a first ASCT, and 73 (61%) had a tandem SCT, including alloSCT in 44 (60%) and ASCT in 29 (40%). The median follow-up was 43 months (4.8-73.7 months). The two-year progression-free survival rate for the whole population and for patients receiving tandem transplant was 56% (95% confidence interval [CI]: 46-65%) and 71% (95% CI: 49-84%), respectively. Among tandem transplants, we observed 20 deaths (17%), 10 of which were transplant-related (6 alloSCT and 4 ASCT). We suggest that tandem SCT is efficient in high-risk relapsed/refractory HL patients, although transplant-related mortality remains high. The benefit of tandem SCT should be balanced with the efficacy of Brentuximab vedotin-based post-transplant consolidative strategies in high-risk relapsed/refractory HL patients.
引用
- Deau B, Amorim S, Perrot A, et al. Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study. Br J Haematol. 2018. PMID: 29611187. doi:10.1111/bjh.15184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。